Merck & Co., Inc. is 43.2x more valuable than Protagonist Therapeutics, Inc by market capitalization ($294.13 B vs $6.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PTGX | MRK |
|---|---|---|
| Market cap | $6.80 B | $294.13 B |
| US-listed rank | #1171 | #44 |
| Revenue (latest FY) | $46.02M | $65.01B |
| Net income (latest FY) | -$130.15M | $18.25B |
| Net margin | -282.8% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 668 | 996 |
Merck & Co., Inc. is 43.2x more valuable than Protagonist Therapeutics, Inc by market capitalization ($294.13 B vs $6.80 B).
In their latest fiscal years, Protagonist Therapeutics, Inc reported $46.02M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Protagonist Therapeutics, Inc and Merck & Co., Inc., or browse the full rankings.